Articles by Hiroshi Sato
Ironwood Pharmaceuticals Survey Reveals Critical Gaps in Short Bowel Syndrome TPN Treatment at DDW 2026
Ironwood Pharmaceuticals presents DDW 2026 survey findings highlighting unmet needs in total parenteral nutrition therapy for short bowel syndrome patients.
Edwards Lifesciences RESILIA Tissue Shows 10-Year Durability in COMMENCE Aortic Trial Results
Edwards Lifesciences announces 10-year COMMENCE trial data demonstrating long-term durability of RESILIA tissue for aortic valve replacement procedures.
Reckitt Benckiser Layoffs Hit NJ: Mucinex Maker Cuts Jobs
Reckitt Benckiser, the company behind Mucinex, has announced further layoffs in New Jersey. This move signals ongoing restructuring within the pharmaceutical giant and reflects broader industry trends.
Reckitt Benckiser Layoffs: Mucinex Maker Cuts Jobs in NJ
Reckitt Benckiser, the company behind Mucinex, has announced further layoffs in New Jersey. This move signals ongoing strategic adjustments within the pharmaceutical giant.
NICE Technology Appraisals: Impact on Market Access for Novel Oncology Drugs
This article examines the role of NICE Technology Appraisals in shaping market access strategies for innovative oncology drugs, including Pembrolizumab.
FDA Guidance on Oncology Drugs: New Rules for Accelerated Approval
The FDA's new guidance on oncology drugs outlines updated rules for accelerated approval, impacting treatments such as Pembrolizumab for various cancers.
Huahui Health Partners with BeOne Medicines for HH160 Trispecific Antibody in Global Oncology Deal
Huahui Health grants BeOne Medicines exclusive worldwide rights to develop HH160, a novel trispecific antibody for cancer immunotherapy treatment.
FDA Approval OncoBlast: Market Impact for Advanced Melanoma
This article analyzes the FDA approval of OncoBlast for advanced melanoma, highlighting its market impact and benefits for patients and healthcare providers.
Ascletis Pharma to Present Diabetes Drug Data at American Diabetes Association 2026 Scientific Sessions
Ascletis Pharma will present clinical data on multiple diabetes programs at the ADA 2026 Scientific Sessions, showcasing pipeline developments in diabetes treatment.
SAHPRA Approval Trastuzumab Deruxtecan: Access & Affordability Insights
Explore the implications of SAHPRA's approval of Trastuzumab Deruxtecan for breast cancer, highlighting key insights on access and affordability.
PMDA SAKIGAKE Designation: Accelerating Innovative Therapies in Japan
The PMDA SAKIGAKE Designation fast-tracks innovative therapies, such as XYZ Drug for cancer, enhancing patient access to groundbreaking treatments in Japan.
Biosimilar Regulation Japan: Aligning PMDA with EMA and FDA Guidelines
This article examines Japan's biosimilar regulations, focusing on how the PMDA aligns with EMA and FDA guidelines to enhance the approval process for drugs like infliximab.
Biosimilar Landscape Japan: PMDA Regulatory Updates & Market Access 2024
Stay informed on Japan's biosimilar landscape with the latest PMDA regulatory updates and market access strategies for 2024, focusing on critical therapies like Adalimumab.
Alzheimer's Clinical Trial Failures: Impact of Posdinemab Phase 2 Failure on Drug Development
The Phase 2 failure of Posdinemab raises critical questions about the future of Alzheimer's drug development and the challenges faced in clinical trials.
Samsung Bioepis Partners with ATLATL Innovation Center to Accelerate Asia-Pacific Biotech Development
Samsung Bioepis and ATLATL Innovation Center sign MoU to accelerate early-stage biotech innovation across Asia-Pacific region through open collaboration.
FDA Approval of Elarekibart: What You Need to Know
Elarekibart has received FDA approval for advanced melanoma treatment, offering new hope for patients with this aggressive skin cancer.
Anixa Biosciences Lira-cel CAR-T Therapy Shows Positive Survival Data in Ovarian Cancer Phase 1 Trial
Anixa Biosciences announces positive survival data for Lira-cel CAR-T therapy in ovarian cancer Phase 1 trial, with presentation at ISCT 2026 meeting.
![NMPA Approval [Drug Name]: Impact on China’s Oncology Market 2025](/uploads/articles/nmpa-approval-drugname-oncology-market-analysis-2025.webp)
NMPA Approval [Drug Name]: Impact on China’s Oncology Market 2025
The NMPA's approval of Drug Name marks a significant milestone for China's oncology market in 2025, promising enhanced treatment options for cancer patients.